Life Sciences Tools 2Q26 Preview: Growth accelerating slightly, but still early in recovery, attractive valuations (Goldman Sachs)
Goldman Sachs released a 2Q26 outlook for life science tools in the Americas.
Goldman Sachs released a 2Q26 outlook for life science tools in the Americas. The GS Tools Tracker showed that market growth accelerated slightly in the second quarter compared with the first quarter, but uncertainty about recovery still exists. China stimulus-related orders fell year-on-year, but Bruker's orders performed outstandingly. The report maintains a positive rating on Thermo Fisher, Danaher and other stocks, believing that the current valuation is a good entry point. One-sentence conclusion: The life science tools industry is in the early stages of recovery, with weak but positive growth signals, overly pessimistic market reactions, and current low valuations providing long-term investors with layout opportunities. Positive/negative: Positive for leaders such as Thermo Fisher (TMO), Danaher (DHR), and Bruker (BRKR). Market concerns about the pace of industry recovery may have been over-priced in stock prices (some of the negative news has been priced in), while the upside risk of earnings revisions has been ignored. Catalysts: 1) Management’s comments on the health of the end market in the 2Q26 financial report; 2) The expected boost in biotech VC financing from the Federal Reserve’s interest rate cut; 3) The implementation effect of China’s stimulus policies.